Prescription of monotherapy 16% was a reason for non-adherence, as various studies have shown that in patients with respiratory shock, combination antibiotic treatment reduces mortality. In addition, a clinical trial conducted in patients with severe community-acquired pneumonia concluded that mortality is higher in patients who received fluoroquinolone versus bitherapy, although statistical significance was not achieved.
Prescripción de monoterapia 16%: varios estudios han demostrado que, en pacientes con shock de origen respiratorio, el tratamiento antibiótico combinado disminuye la mortalidad; además, un ensayo clínico realizado en pacientes con neumonía comunitaria grave concluye que la mortalidad es mayor en pacientes que reciben fluoroquinolona versus biterapia, aunque sin alcanzar diferencias estadísticamente significativas.